SR9009 (Stenabolic)

Compelling rodent data for metabolism and endurance, but oral bioavailability in humans is likely very poor. No human clinical trials.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Mouse studies showed increased running endurance, fat loss, and altered circadian gene expression. A pharmacokinetic analysis suggests oral bioavailability may be under 5% in primates, raising questions about whether oral dosing achieves effective concentrations in humans.

• Robust endurance and fat-loss effects in mice
• Modulates circadian metabolism pathways
• Reduced anxiety-like behavior in animal models

No human dosing established. Mouse studies used 100 mg/kg IP injection.

• Unknown in humans
• Poor oral bioavailability may render oral use ineffective

Extremely low oral bioavailability likely limits human efficacy of oral formulations. Not approved for human use.

The disconnect between dramatic mouse results and poor oral bioavailability is the central issue. Injectable or sublingual routes are unvalidated.

• Energy30
• Weight loss25
• Longevity20